Atlas Trials

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

Clinical trial NCT05596266 · UNKNOWN

Trial details

NCT number
NCT05596266
Sponsor
Xuanwu Hospital, Beijing
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
T-cell Acute Lymphoblastic Leukemia
Start date
2022-10-25
Primary completion
2024-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.